These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 18640946)

  • 1. Trial design for metastatic castration-resistant prostate cancer.
    Sonpavde G; Fleming MT; Hutson TE; Galsky MD
    J Clin Oncol; 2008 Jul; 26(21):3647-8; author reply 3648-9. PubMed ID: 18640946
    [No Abstract]   [Full Text] [Related]  

  • 2. [The survival analysis of the advanced metastatic castration-resistant prostate cancer].
    Ma CG; Ye DW; Yao XD; Zhang SL; Dai B; Zhang HL; Zhu Y; Shen YJ; Zhu YP; Shi GH; Qin XJ; Lin GW; Yang LF; Yang BS; Xiao WJ
    Zhonghua Wai Ke Za Zhi; 2009 Nov; 47(22):1712-4. PubMed ID: 20137723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy in patients with castration-resistant prostate cancer.
    Meulenbeld HJ; Hamberg P; de Wit R
    Eur J Cancer; 2009 Sep; 45 Suppl 1():161-71. PubMed ID: 19775615
    [No Abstract]   [Full Text] [Related]  

  • 4. Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer.
    Park YH; Hwang IS; Jeong CW; Kim HH; Lee SE; Kwak C
    J Urol; 2009 Jun; 181(6):2520-4; discussion 2525. PubMed ID: 19371894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paradigms in androgen/castrate resistant states of prostate cancer in a biomarker era.
    Bianco FJ
    Urol Oncol; 2008; 26(4):408-14. PubMed ID: 18593619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic therapeutic strategies for prostate cancer.
    Nelson WG
    Clin Adv Hematol Oncol; 2005 Aug; 3(8):619-21. PubMed ID: 16167046
    [No Abstract]   [Full Text] [Related]  

  • 7. Survival analyses overview in hormone-refractory prostate cancer clinical trials in the prostate-specific antigen era.
    Sartor O
    Clin Genitourin Cancer; 2007 Dec; 5(7):420-1. PubMed ID: 18272022
    [No Abstract]   [Full Text] [Related]  

  • 8. [Interest of the radiotherapy-hormonotherapy association in the treatment of the high-risk prostate cancer].
    Bolla M; Fourneret P; Descotes JL
    Bull Cancer; 2008 Dec; 95(12):1213-8. PubMed ID: 19091656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel concepts in androgen receptor blockade.
    Hsieh AC; Ryan CJ
    Cancer J; 2008; 14(1):11-4. PubMed ID: 18303477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New drug development in metastatic prostate cancer.
    Armstrong AJ; George DJ
    Urol Oncol; 2008; 26(4):430-7. PubMed ID: 18593623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined androgen blockade revisited: emerging options for the treatment of castration-resistant prostate cancer.
    Simmons MN; Klein EA
    Urology; 2009 Apr; 73(4):697-705. PubMed ID: 19185908
    [No Abstract]   [Full Text] [Related]  

  • 13. Cytology of metastatic prostate cancer following orchiectomy and antiandrogen therapy: a diagnostic challenge.
    Rapkiewicz A; Gorokhovsky R; Farcon E; Das K
    Diagn Cytopathol; 2008 Jul; 36(7):499-502. PubMed ID: 18528888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cancer of the prostate: importance of androgen deprivation and radiotherapy].
    Rentsch CA; Aebersold DM; Merz V; Studer UE
    Rev Med Suisse; 2005 May; 1(19):1303-6. PubMed ID: 15962630
    [No Abstract]   [Full Text] [Related]  

  • 15. Intermittent androgen blockade should be regarded as standard therapy in prostate cancer.
    Seruga B; Tannock IF
    Nat Clin Pract Oncol; 2008 Oct; 5(10):574-6. PubMed ID: 18628739
    [No Abstract]   [Full Text] [Related]  

  • 16. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
    Soga N; Arima K; Sugimura Y
    Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
    Abouassaly R; Paciorek A; Ryan CJ; Carroll PR; Klein EA
    Cancer; 2009 Oct; 115(19):4470-6. PubMed ID: 19637339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prostate cancer prevention trial: design, biases and interpretation of study results.
    Goodman PJ; Thompson IM; Tangen CM; Crowley JJ; Ford LG; Coltman CA
    J Urol; 2006 Jun; 175(6):2234-42. PubMed ID: 16697846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trials for prostate cancer.
    Harv Mens Health Watch; 2002 Mar; 6(8):5-8. PubMed ID: 11916650
    [No Abstract]   [Full Text] [Related]  

  • 20. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
    Scher HI; Halabi S; Tannock I; Morris M; Sternberg CN; Carducci MA; Eisenberger MA; Higano C; Bubley GJ; Dreicer R; Petrylak D; Kantoff P; Basch E; Kelly WK; Figg WD; Small EJ; Beer TM; Wilding G; Martin A; Hussain M;
    J Clin Oncol; 2008 Mar; 26(7):1148-59. PubMed ID: 18309951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.